What is the appropriate workup for suspected acute interstitial nephritis?

Workup for Suspected Acute Interstitial Nephritis

The workup for suspected AIN centers on excluding alternative causes of AKI through targeted laboratory and clinical assessment, with kidney biopsy reserved for cases where the diagnosis remains uncertain after initial evaluation or when renal function fails to improve within 5-7 days of removing the suspected offending agent 1, 2.

Initial Laboratory Assessment

When AIN is suspected, obtain the following tests immediately:

• Serial serum creatinine measurements (at least two consecutive values to document sustained elevation ≥50% above baseline) 1
• Urinalysis with microscopy looking specifically for:
  • Sterile pyuria (≥5 WBCs/hpf) - present in most cases 1, 3
  • White blood cell casts (when present, highly suggestive)
  • Hematuria (present in only ~33% of cases) 3
  • Subnephrotic proteinuria (typically <1-2g/day) 3
• Urine culture to exclude urinary tract infection 1
• Complete blood count checking for peripheral eosinophilia (≥500 cells/mL), though this occurs in only ~15-20% of cases 1, 3
• Comprehensive metabolic panel to assess baseline renal function and electrolyte disturbances 4

Critical Clinical Evaluation

Systematically exclude alternative causes before attributing AKI to AIN 1:

• Medication review: Document ALL medications including over-the-counter drugs, herbals, vitamins, NSAIDs, PPIs, and antibiotics - the most common culprits 1, 4
• Recent IV contrast exposure (within 48-72 hours) 1
• Volume status assessment: Evaluate for pre-renal causes through physical examination and review of fluid balance 1
• Obstruction evaluation: Obtain renal ultrasound with Doppler if obstruction is suspected 5
• Concomitant extrarenal immune-related adverse events (particularly in checkpoint inhibitor-associated cases) 1

Important Diagnostic Caveats

The classic triad of fever, rash, and arthralgias is absent in up to two-thirds of patients with AIN 6. Do not rely on these findings to make or exclude the diagnosis. Similarly, urine eosinophils and gallium-67 scanning lack sufficient sensitivity and specificity to reliably confirm or exclude AIN 6.

When to Perform Kidney Biopsy

Kidney biopsy should be considered in the following scenarios 1, 2:

• No improvement in renal function 5-7 days after withdrawal of the suspected causative agent 2
• Uncertainty about the diagnosis when multiple potential etiologies exist 7
• Severe AKI (KDIGO stage 3: creatinine ≥3× baseline or ≥4.0 mg/dL) where definitive diagnosis would alter management 1
• Need to assess prognosis based on histologic features (degree of interstitial fibrosis and tubular atrophy) 4

However, biopsy can be deferred if there is rapid clinical improvement after removing the offending agent and no alternative diagnosis is suspected 6. In checkpoint inhibitor-associated nephritis specifically, reflex kidney biopsy should be discouraged until steroid treatment has been attempted 1.

Diagnostic Criteria Framework

Use this hierarchical approach for diagnosis 1:

Definite AIN: Kidney biopsy-confirmed diagnosis showing tubulointerstitial inflammation with lymphocytic infiltrate, after clinical review of risk factors

Probable AIN:

• Sustained creatinine increase ≥50% on consecutive values AND
• Absence of alternative plausible etiology AND
• At least one of: sterile pyuria (≥5 WBCs/hpf) OR peripheral eosinophilia (≥500 cells/mL) OR concomitant extrarenal immune-related adverse event

Possible AIN:

• Creatinine increase ≥50% AND
• AKI not readily attributable to alternative causes

Emerging Biomarkers

While not yet standard of care, research suggests that CXCL9, TNF-alpha, IL-9, and urinary RANTES show promise as diagnostic biomarkers for AIN 8, 7. However, these require validation in larger studies before clinical implementation.

Key Pitfalls to Avoid

• Do not assume drug-induced AIN without excluding infection-related causes, particularly acute pyelonephritis, which can present identically but requires different treatment (antibiotics rather than steroids) 9
• Do not delay withdrawal of suspected causative medications while awaiting diagnostic confirmation - early removal is the single most important intervention 4, 2
• Do not perform routine urinalysis in all patients on checkpoint inhibitors; monitor serum creatinine before each dose and obtain urinalysis only when AKI is detected 1
• Do not rely on the absence of eosinophilia or classic symptoms to exclude AIN - most cases lack these findings 6, 3